242 related articles for article (PubMed ID: 34549539)
1. Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety.
Oaknin A; Oza AM; Lorusso D; Aghajanian C; Dean A; Colombo N; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Amenedo Gancedo M; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Cameron T; Maloney L; Goble S; Ledermann JA; Coleman RL
Cancer Med; 2021 Oct; 10(20):7162-7173. PubMed ID: 34549539
[TBL] [Abstract][Full Text] [Related]
2. Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3.
Clamp AR; Lorusso D; Oza AM; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Scambia G; Leary A; Holloway RW; Amenedo Gancedo M; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Cameron T; Goble S; Coleman RL; Ledermann JA
Int J Gynecol Cancer; 2021 Jul; 31(7):949-958. PubMed ID: 34103386
[TBL] [Abstract][Full Text] [Related]
3. Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Coleman RL; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp A; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Garcia-Donas J; Swisher EM; Floquet A; Konecny GE; McNeish IA; Scott CL; Cameron T; Maloney L; Isaacson J; Goble S; Grace C; Harding TC; Raponi M; Sun J; Lin KK; Giordano H; Ledermann JA;
Lancet; 2017 Oct; 390(10106):1949-1961. PubMed ID: 28916367
[TBL] [Abstract][Full Text] [Related]
4. Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial.
Ledermann JA; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Cameron T; Maloney L; Goble S; Coleman RL
Lancet Oncol; 2020 May; 21(5):710-722. PubMed ID: 32359490
[TBL] [Abstract][Full Text] [Related]
5. Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients With Recurrent Ovarian Carcinoma.
Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Cella D; Meunier J; Goble S; Cameron T; Maloney L; Mörk AC; Bedel J; Ledermann JA; Coleman RL
J Clin Oncol; 2020 Oct; 38(30):3494-3505. PubMed ID: 32840418
[TBL] [Abstract][Full Text] [Related]
6. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.
Swisher EM; Lin KK; Oza AM; Scott CL; Giordano H; Sun J; Konecny GE; Coleman RL; Tinker AV; O'Malley DM; Kristeleit RS; Ma L; Bell-McGuinn KM; Brenton JD; Cragun JM; Oaknin A; Ray-Coquard I; Harrell MI; Mann E; Kaufmann SH; Floquet A; Leary A; Harding TC; Goble S; Maloney L; Isaacson J; Allen AR; Rolfe L; Yelensky R; Raponi M; McNeish IA
Lancet Oncol; 2017 Jan; 18(1):75-87. PubMed ID: 27908594
[TBL] [Abstract][Full Text] [Related]
7. The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma.
Colombo N; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; O'Malley DM; Armstrong DK; Banerjee S; García-Donas J; Swisher EM; Meunier J; Cameron T; Maloney L; Goble S; Bedel J; Ledermann JA; Coleman RL
Gynecol Oncol; 2020 Oct; 159(1):101-111. PubMed ID: 32861537
[TBL] [Abstract][Full Text] [Related]
8. Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian carcinoma.
O'Malley DM; Oza AM; Lorusso D; Aghajanian C; Oaknin A; Dean A; Colombo N; Weberpals JI; Clamp AR; Scambia G; Leary A; Holloway RW; Gancedo MA; Fong PC; Goh JC; Swisher EM; Maloney L; Goble S; Lin KK; Kwan T; Ledermann JA; Coleman RL
Gynecol Oncol; 2022 Dec; 167(3):404-413. PubMed ID: 36273926
[TBL] [Abstract][Full Text] [Related]
9. A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA-MONO/GOG-3020/ENGOT-ov45).
Monk BJ; Parkinson C; Lim MC; O'Malley DM; Oaknin A; Wilson MK; Coleman RL; Lorusso D; Bessette P; Ghamande S; Christopoulou A; Provencher D; Prendergast E; Demirkiran F; Mikheeva O; Yeku O; Chudecka-Glaz A; Schenker M; Littell RD; Safra T; Chou HH; Morgan MA; Drochýtek V; Barlin JN; Van Gorp T; Ueland F; Lindahl G; Anderson C; Collins DC; Moore K; Marme F; Westin SN; McNeish IA; Shih D; Lin KK; Goble S; Hume S; Fujiwara K; Kristeleit RS
J Clin Oncol; 2022 Dec; 40(34):3952-3964. PubMed ID: 35658487
[TBL] [Abstract][Full Text] [Related]
10. Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.
Pujade-Lauraine E; Selle F; Scambia G; Asselain B; Marmé F; Lindemann K; Colombo N; Mądry R; Glasspool R; Vergote I; Korach J; Lheureux S; Dubot C; Oaknin A; Zamagni C; Heitz F; Gladieff L; Rubio-Pérez MJ; Scollo P; Blakeley C; Shaw B; Ray-Coquard I; Redondo A;
Ann Oncol; 2023 Dec; 34(12):1152-1164. PubMed ID: 37797734
[TBL] [Abstract][Full Text] [Related]
11. ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.
Monk BJ; Coleman RL; Fujiwara K; Wilson MK; Oza AM; Oaknin A; O'Malley DM; Lorusso D; Westin SN; Safra T; Herzog TJ; Marmé F; N Eskander R; Lin KK; Shih D; Goble S; Grechko N; Hume S; Maloney L; McNeish IA; Kristeleit RS
Int J Gynecol Cancer; 2021 Dec; 31(12):1589-1594. PubMed ID: 34593565
[TBL] [Abstract][Full Text] [Related]
12. Patient-reported outcomes of maintenance rucaparib in patients with recurrent ovarian carcinoma in ARIEL3, a phase III, randomized, placebo-controlled trial.
Peipert JD; Goble S; Isaacson J; Tang X; Wallace K; Coleman RL; Ledermann JA; Cella D
Gynecol Oncol; 2023 Aug; 175():1-7. PubMed ID: 37262961
[TBL] [Abstract][Full Text] [Related]
13. Rucaparib: A Review in Ovarian Cancer.
Shirley M
Target Oncol; 2019 Apr; 14(2):237-246. PubMed ID: 30830551
[TBL] [Abstract][Full Text] [Related]
14. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
[TBL] [Abstract][Full Text] [Related]
15. Mathematical modeling of the early modeled CA-125 longitudinal kinetics (KELIM-PARP) as a pragmatic indicator of rucaparib efficacy in patients with recurrent ovarian carcinoma in ARIEL2 & STUDY 10.
Colomban O; Swisher EM; Kristeleit R; McNeish I; Shapira-Frommer R; Goble S; Lin KK; Maloney L; Freyer G; You B
EBioMedicine; 2023 Mar; 89():104477. PubMed ID: 36801617
[TBL] [Abstract][Full Text] [Related]
16. Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor in patients with newly diagnosed advanced epithelial ovarian cancer: individual patient data and trial-level meta-analysis.
Gulia S; Kannan S; Ghosh J; Rath S; Maheshwari A; Gupta S
ESMO Open; 2022 Oct; 7(5):100558. PubMed ID: 36007449
[TBL] [Abstract][Full Text] [Related]
17. Rucaparib: a novel PARP inhibitor for
Colombo I; Lheureux S; Oza AM
Drug Des Devel Ther; 2018; 12():605-617. PubMed ID: 29606854
[TBL] [Abstract][Full Text] [Related]
18. Fuzuloparib Maintenance Therapy in Patients With Platinum-Sensitive, Recurrent Ovarian Carcinoma (FZOCUS-2): A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Trial.
Li N; Zhang Y; Wang J; Zhu J; Wang L; Wu X; Yao D; Wu Q; Liu J; Tang J; Yin R; Lou G; An R; Zhang G; Xia X; Li Q; Zhu Y; Zheng H; Yang X; Hu Y; Zhang X; Hao M; Huang Y; Lin Z; Wang D; Guo X; Yao S; Wan X; Zhou H; Yao L; Yang X; Cui H; Meng Y; Zhang S; Qu J; Zhang B; Zou J; Wu L
J Clin Oncol; 2022 Aug; 40(22):2436-2446. PubMed ID: 35404684
[TBL] [Abstract][Full Text] [Related]
19. Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer.
Musella A; Bardhi E; Marchetti C; Vertechy L; Santangelo G; Sassu C; Tomao F; Rech F; D'Amelio R; Monti M; Palaia I; Muzii L; Benedetti Panici P
Cancer Treat Rev; 2018 May; 66():7-14. PubMed ID: 29605737
[TBL] [Abstract][Full Text] [Related]
20. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Dougherty B; Orr M; Hodgson D; Barrett JC; Matulonis U
Lancet Oncol; 2014 Jul; 15(8):852-61. PubMed ID: 24882434
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]